Therefore, we performed statistical analysis on the expression levels of CSF1R, CDK6, FLT3 and KMT2A (MLL) between sensitive AML cell lines to narazaciclib and insensitive AML cell lines (Fig. 1B–G and Table 1). This evidence concerns the gene KMT2A and acute myeloid leukemia.